{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:11:11Z","timestamp":1790194271256,"version":"4.1.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AI148557-01A1"],"award-info":[{"award-number":["1R01AI148557-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1156262"],"award-info":[{"award-number":["OPP1156262"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["428410"],"award-info":[{"award-number":["428410"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Malaria parasite transmission remains a barrier to elimination since asymptomatic individuals sustain the infectious reservoir. Transmission-blocking vaccine (TBV) candidates targeting\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    (Pf) gametocyte surface proteins Pfs230 and Pfs48\/45 have shown promise in clinical trials. Several vaccine candidates have been developed for these antigens, yet it is unclear which elicit the most robust and durable transmission-blocking responses. From structure-function relationships of monoclonal antibodies in complex with both antigens, we report the development of a stabilized tandem antigen chimera (STAC), which presents the most potent epitopes from Pfs230 domain 1\u00a0(Pfs230-D1) and Pfs48\/45 domain 3\u00a0(Pfs48\/45-D3) in a single construct, while masking non-functional epitopes using an engineered pseudo-native domain disposition. Iterative structure-guided optimization improved antigen yields and stability, while nanoparticle-based multimerization enhanced the functional transmission-reducing activity elicited by the immunogen in female mice. Immunizations with STAC genetically conjugated to self-assembling protein nanoparticles elicited antibodies with potent transmission-reducing activity comparable or superior to the multimerized Pfs230-D1 and Pfs48\/45-D3. These findings establish STAC as a promising next-generation TBV candidate to disrupt malaria transmission and accelerate elimination efforts. More broadly, our results support the engineering of highly ordered and stable multi-domain antigens in a single protein as a strategy for the cost-efficient development of multi-component vaccines.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-68761-1","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T15:47:34Z","timestamp":1769269654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A stabilized tandem antigen chimera that elicits potent malaria transmission-reducing activity"],"prefix":"10.1038","volume":"17","author":[{"given":"Danton","family":"Ivanochko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-2432","authenticated-orcid":false,"given":"Kazutoyo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Hailemariam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rianne","family":"Stoter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Teelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert-Jan","family":"van Gemert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Leaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sidney","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Men","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Semesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Shiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4566-1481","authenticated-orcid":false,"given":"Randall S.","family":"MacGill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-5443","authenticated-orcid":false,"given":"Carole A.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0686-370X","authenticated-orcid":false,"given":"Matthijs M.","family":"Jore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2978-4692","authenticated-orcid":false,"given":"Neil P.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9052-884X","authenticated-orcid":false,"given":"Jonathan F.","family":"Lovell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7602-3995","authenticated-orcid":false,"given":"Jean-Philippe","family":"Julien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"68761_CR1","unstructured":"World Health Organization. World malaria report 2024: addressing inequity in the global malaria response. https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2024."},{"key":"68761_CR2","doi-asserted-by":"crossref","unstructured":"RTS,S. Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet Lond. Engl. 386, 31\u201345 (2015).","DOI":"10.1016\/S0140-6736(15)60721-8"},{"key":"68761_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","volume":"403","author":"MS Datoo","year":"2024","unstructured":"Datoo, M. S. et al. Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial. Lancet Lond. Engl. 403, 533\u2013544 (2024).","journal-title":"Lancet Lond. Engl."},{"key":"68761_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1473-3099(23)00368-7","volume":"24","author":"A Dicko","year":"2024","unstructured":"Dicko, A. et al. Seasonal vaccination with RTS,S\/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial. Lancet Infect. Dis. 24, 75\u201386 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"68761_CR5","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1016\/S1473-3099(21)00072-4","volume":"21","author":"C Andolina","year":"2021","unstructured":"Andolina, C. et al. Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study. Lancet Infect. Dis. 21, 1568\u20131578 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"68761_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-023-04736-7","volume":"22","author":"A Biruksew","year":"2023","unstructured":"Biruksew, A. et al. Schoolchildren with asymptomatic malaria are a potential hotspot for malaria reservoir in Ethiopia: implications for malaria control and elimination efforts. Malar. J. 22, 311 (2023).","journal-title":"Malar. J."},{"key":"68761_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01270-4","volume":"8","author":"BP Gon\u00e7alves","year":"2017","unstructured":"Gon\u00e7alves, B. P. et al. Examining the human infectious reservoir for Plasmodium falciparum malaria in areas of differing transmission intensity. Nat. Commun. 8, 1133 (2017).","journal-title":"Nat. Commun."},{"key":"68761_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0009672","volume":"15","author":"C Koepfli","year":"2021","unstructured":"Koepfli, C. et al. Identification of the asymptomatic Plasmodium falciparum and Plasmodium vivax gametocyte reservoir under different transmission intensities. PLoS Negl. Trop. Dis. 15, e0009672 (2021).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"68761_CR9","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1093\/cid\/cix1123","volume":"66","author":"FG Tadesse","year":"2018","unstructured":"Tadesse, F. G. et al. The relative contribution of symptomatic and asymptomatic Plasmodium vivax and Plasmodium falciparum infections to the infectious reservoir in a low-endemic setting in Ethiopia. Clin. Infect. Dis. 66, 1883\u20131891 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"68761_CR10","doi-asserted-by":"publisher","first-page":"e00145","DOI":"10.1016\/j.parepi.2020.e00145","volume":"10","author":"MA Penny","year":"2020","unstructured":"Penny, M. A., Camponovo, F., Chitnis, N., Smith, T. A. & Tanner, M. Future use-cases of vaccines in malaria control and elimination. Parasite Epidemiol. Control 10, e00145 (2020).","journal-title":"Parasite Epidemiol. Control"},{"key":"68761_CR11","doi-asserted-by":"publisher","first-page":"e680","DOI":"10.1016\/S2214-109X(17)30220-6","volume":"5","author":"OJ Brady","year":"2017","unstructured":"Brady, O. J. et al. Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study. Lancet Glob. Health 5, e680\u2013e687 (2017).","journal-title":"Lancet Glob. Health"},{"key":"68761_CR12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/s41579-024-01065-7","volume":"22","author":"PE Duffy","year":"2024","unstructured":"Duffy, P. E., Gorres, J. P., Healy, S. A. & Fried, M. Malaria vaccines: a new era of prevention and control. Nat. Rev. Microbiol. 22, 756\u2013772 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"68761_CR13","doi-asserted-by":"publisher","first-page":"e70001","DOI":"10.1111\/imr.70001","volume":"330","author":"R Yoo","year":"2025","unstructured":"Yoo, R., Jore, M. M. & Julien, J.-P. Targeting bottlenecks in malaria transmission: antibody-epitope descriptions guide the design of next-generation biomedical interventions. Immunol. Rev. 330, e70001 (2025).","journal-title":"Immunol. Rev."},{"key":"68761_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0166-6851(99)00066-3","volume":"101","author":"TJ Templeton","year":"1999","unstructured":"Templeton, T. J. & Kaslow, D. C. Identification of additional members defines a Plasmodium falciparum gene superfamily which includes Pfs48\/45 and Pfs230. Mol. Biochem. Parasitol. 101, 223\u2013227 (1999).","journal-title":"Mol. Biochem. Parasitol."},{"key":"68761_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/j.1365-2958.2006.05284.x","volume":"61","author":"S Eksi","year":"2006","unstructured":"Eksi, S. et al. Malaria transmission-blocking antigen, Pfs230, mediates human red blood cell binding to exflagellating male parasites and oocyst production. Mol. Microbiol. 61, 991\u2013998 (2006).","journal-title":"Mol. Microbiol."},{"key":"68761_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33236-x","volume":"8","author":"C Marin-Mogollon","year":"2018","unstructured":"Marin-Mogollon, C. et al. The Plasmodium falciparum male gametocyte protein P230p, a paralog of P230, is vital for ookinete formation and mosquito transmission. Sci. Rep. 8, 14902 (2018).","journal-title":"Sci. Rep."},{"key":"68761_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/S0092-8674(01)00199-4","volume":"104","author":"MR van Dijk","year":"2001","unstructured":"van Dijk, M. R. et al. A central role for P48\/45 in malaria parasite male gamete fertility. Cell 104, 153\u2013164 (2001).","journal-title":"Cell"},{"key":"68761_CR18","doi-asserted-by":"crossref","unstructured":"Bekkering, E. T. et al. Cryo-EM structure of endogenous Pfs230:Pfs48\/45 complex with six antibodies reveals mechanisms of malaria transmission-blocking activity. Immunity, Vol. 58, 2899\u2013916.e10 (Elsevier, 2025).","DOI":"10.1016\/j.immuni.2025.09.014"},{"key":"68761_CR19","doi-asserted-by":"crossref","unstructured":"Dietrich, M. H. et al. Cryo-EM structure of endogenous Plasmodium falciparum Pfs230 and Pfs48\/45 fertilization complex. Science 389, eady0241 (2025).","DOI":"10.1126\/science.ady0241"},{"key":"68761_CR20","doi-asserted-by":"publisher","first-page":"19913","DOI":"10.1074\/jbc.M116.732305","volume":"291","author":"NJ MacDonald","year":"2016","unstructured":"MacDonald, N. J. et al. Structural and immunological characterization of recombinant 6-cysteine domains of the Plasmodium falciparum sexual stage protein Pfs230. J. Biol. Chem. 291, 19913\u201319922 (2016).","journal-title":"J. Biol. Chem."},{"key":"68761_CR21","doi-asserted-by":"publisher","first-page":"5762","DOI":"10.1016\/j.vaccine.2018.09.037","volume":"37","author":"M Burkhardt","year":"2019","unstructured":"Burkhardt, M. et al. Assessment of the impact of manufacturing changes on the physicochemical properties of the recombinant vaccine carrier ExoProtein A. Vaccine 37, 5762\u20135769 (2019).","journal-title":"Vaccine"},{"key":"68761_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-024-03379-y","volume":"22","author":"M Alkema","year":"2024","unstructured":"Alkema, M. et al. A Pfs48\/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trial. BMC Med. 22, 170 (2024).","journal-title":"BMC Med."},{"key":"68761_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00929-6","volume":"9","author":"CH Coelho","year":"2024","unstructured":"Coelho, C. H. et al. Antibody gene features associated with binding and functional activity in malaria vaccine-derived human mAbs. NPJ Vaccines 9, 144 (2024).","journal-title":"NPJ Vaccines"},{"key":"68761_CR24","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1473-3099(23)00276-1","volume":"23","author":"I Sagara","year":"2023","unstructured":"Sagara, I. et al. Malaria transmission-blocking vaccines Pfs230D1-EPA and Pfs25-EPA in Alhydrogel in healthy Malian adults; a phase 1, randomised, controlled trial. Lancet Infect. Dis. 23, 1266\u20131279 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"68761_CR25","doi-asserted-by":"publisher","first-page":"e146221, 146221","DOI":"10.1172\/JCI146221","volume":"131","author":"SA Healy","year":"2021","unstructured":"Healy, S. A. et al. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice. J. Clin. Invest. 131, e146221, 146221 (2021).","journal-title":"J. Clin. Invest."},{"key":"68761_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21955-1","volume":"12","author":"CH Coelho","year":"2021","unstructured":"Coelho, C. H. et al. A human monoclonal antibody blocks malaria transmission and defines a highly conserved neutralizing epitope on gametes. Nat. Commun. 12, 1750 (2021).","journal-title":"Nat. Commun."},{"key":"68761_CR27","doi-asserted-by":"publisher","DOI":"10.1172\/JCI175707","volume":"134","author":"AB Tiono","year":"2024","unstructured":"Tiono, A. B. et al. A randomized first-in-human phase I trial of differentially adjuvanted Pfs48\/45 malaria vaccines in Burkinab\u00e9 adults. J. Clin. Invest. 134, e175707 (2024).","journal-title":"J. Clin. Invest."},{"key":"68761_CR28","doi-asserted-by":"publisher","first-page":"2488075","DOI":"10.1080\/21645515.2025.2488075","volume":"21","author":"M Naghizadeh","year":"2025","unstructured":"Naghizadeh, M. et al. Magnitude and durability of ProC6C-AlOH\/Matrix-Mtm vaccine-induced malaria transmission-blocking antibodies in Burkinabe adults from a Phase 1 randomized trial. Hum. Vaccines Immunother. 21, 2488075 (2025).","journal-title":"Hum. Vaccines Immunother."},{"key":"68761_CR29","doi-asserted-by":"publisher","first-page":"1589061","DOI":"10.3389\/fimmu.2025.1589061","volume":"16","author":"C Mulamba","year":"2025","unstructured":"Mulamba, C. et al. Seroprevalence of antibodies to Plasmodium falciparum transmission-blocking target proteins Pfs230D1M and Pfs48\/45 in Tanzanian populations of diverse malaria transmission intensity. Front. Immunol. 16, 1589061 (2025).","journal-title":"Front. Immunol."},{"key":"68761_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0014114","volume":"5","author":"T Bousema","year":"2010","unstructured":"Bousema, T. et al. The dynamics of naturally acquired immune responses to Plasmodium falciparum sexual stage antigens Pfs230 & Pfs48\/45 in a low-endemic area in Tanzania. PloS One 5, e14114 (2010).","journal-title":"PloS One"},{"key":"68761_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-8-127","volume":"8","author":"F Tediosi","year":"2009","unstructured":"Tediosi, F., Maire, N., Penny, M., Studer, A. & Smith, T. A. Simulation of the cost-effectiveness of malaria vaccines. Malar. J. 8, 127 (2009).","journal-title":"Malar. J."},{"key":"68761_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1365-3024.1994.tb00305.x","volume":"16","author":"D Read","year":"1994","unstructured":"Read, D. et al. Transmission-blocking antibodies against multiple, non-variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement-fixing. Parasite Immunol. 16, 511\u2013519 (1994).","journal-title":"Parasite Immunol."},{"key":"68761_CR33","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.immuni.2023.01.012","volume":"56","author":"WK Tang","year":"2023","unstructured":"Tang, W. K. et al. A human antibody epitope map of Pfs230D1 derived from analysis of individuals vaccinated with a malaria transmission-blocking vaccine. Immunity 56, 433\u2013443.e5 (2023).","journal-title":"Immunity"},{"key":"68761_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.immuni.2023.01.013","volume":"56","author":"D Ivanochko","year":"2023","unstructured":"Ivanochko, D. et al. Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230. Immunity 56, 420\u2013432.e7 (2023).","journal-title":"Immunity"},{"key":"68761_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00784-x","volume":"8","author":"MR Inklaar","year":"2023","unstructured":"Inklaar, M. R. et al. Pfs230 Domain 7 is targeted by a potent malaria transmission-blocking monoclonal antibody. NPJ Vaccines 8, 186 (2023).","journal-title":"NPJ Vaccines"},{"key":"68761_CR36","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s42003-020-01123-9","volume":"3","author":"K Singh","year":"2020","unstructured":"Singh, K. et al. Structure and function of a malaria transmission blocking vaccine targeting Pfs230 and Pfs230-Pfs48\/45 proteins. Commun. Biol. 3, 395 (2020).","journal-title":"Commun. Biol."},{"key":"68761_CR37","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.immuni.2023.01.009","volume":"56","author":"A Fabra-Garc\u00eda","year":"2023","unstructured":"Fabra-Garc\u00eda, A. et al. Highly potent, naturally acquired human monoclonal antibodies against Pfs48\/45 block Plasmodium falciparum transmission to mosquitoes. Immunity 56, 406\u2013419.e7 (2023).","journal-title":"Immunity"},{"key":"68761_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-06340-9","volume":"9","author":"F Lennartz","year":"2018","unstructured":"Lennartz, F. et al. Structural basis for recognition of the malaria vaccine candidate Pfs48\/45 by a transmission blocking antibody. Nat. Commun. 9, 3822 (2018).","journal-title":"Nat. Commun."},{"key":"68761_CR39","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3389\/fimmu.2019.01256","volume":"10","author":"SK Singh","year":"2019","unstructured":"Singh, S. K. et al. Pfs230 and Pfs48\/45 fusion proteins elicit strong transmission-blocking antibody responses against Plasmodium falciparum. Front. Immunol. 10, 1256 (2019).","journal-title":"Front. Immunol."},{"key":"68761_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00383-8","volume":"6","author":"SK Singh","year":"2021","unstructured":"Singh, S. K. et al. Preclinical development of a Pfs230-Pfs48\/45 chimeric malaria transmission-blocking vaccine. NPJ Vaccines 6, 120 (2021).","journal-title":"NPJ Vaccines"},{"key":"68761_CR41","doi-asserted-by":"publisher","first-page":"1481829","DOI":"10.3389\/fimmu.2024.1481829","volume":"15","author":"J Plieskatt","year":"2024","unstructured":"Plieskatt, J. et al. ProC6C, a novel multi-stage malaria vaccine, elicits functional antibodies against the minor and central repeats of the Circumsporozoite Protein in human adults. Front. Immunol. 15, 1481829 (2024).","journal-title":"Front. Immunol."},{"key":"68761_CR42","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1016\/j.immuni.2022.07.015","volume":"55","author":"B McLeod","year":"2022","unstructured":"McLeod, B. et al. Vaccination with a structure-based stabilized version of malarial antigen Pfs48\/45 elicits ultra-potent transmission-blocking antibody responses. Immunity 55, 1680\u20131692.e8 (2022).","journal-title":"Immunity"},{"key":"68761_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00619-9","volume":"8","author":"TH Dickey","year":"2023","unstructured":"Dickey, T. H. et al. Design of a stabilized non-glycosylated Pfs48\/45 antigen enables a potent malaria transmission-blocking nanoparticle vaccine. NPJ Vaccines 8, 20 (2023).","journal-title":"NPJ Vaccines"},{"key":"68761_CR44","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1126\/science.add2187","volume":"378","author":"J Dauparas","year":"2022","unstructured":"Dauparas, J. et al. Robust deep learning-based protein sequence design using ProteinMPNN. Science 378, 49\u201356 (2022).","journal-title":"Science"},{"key":"68761_CR45","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","volume":"620","author":"JL Watson","year":"2023","unstructured":"Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089\u20131100 (2023).","journal-title":"Nature"},{"key":"68761_CR46","doi-asserted-by":"publisher","first-page":"4357","DOI":"10.1021\/acsnano.0c07680","volume":"15","author":"X He","year":"2021","unstructured":"He, X. et al. A potent cancer vaccine adjuvant system for particleization of short, synthetic CD8+ T cell epitopes. ACS Nano 15, 4357\u20134371 (2021).","journal-title":"ACS Nano"},{"key":"68761_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-019-2989-2","volume":"18","author":"S-M Lee","year":"2019","unstructured":"Lee, S.-M. et al. The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate. Malar. J. 18, 356 (2019).","journal-title":"Malar. J."},{"key":"68761_CR48","doi-asserted-by":"publisher","first-page":"e57909","DOI":"10.1371\/journal.pone.0057909","volume":"8","author":"K Miura","year":"2013","unstructured":"Miura, K. et al. Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays. PLoS ONE 8, e57909 (2013).","journal-title":"PLoS ONE"},{"key":"68761_CR49","doi-asserted-by":"crossref","unstructured":"Kucharska, I. et al. Structural elucidation of full-length Pfs48\/45 in complex with potent monoclonal antibodies isolated from a naturally exposed individual. Nat. Struct. Mol. Biol. 32, 1396\u20131407 (2025).","DOI":"10.1038\/s41594-025-01532-6"},{"key":"68761_CR50","doi-asserted-by":"crossref","unstructured":"Xu, J. & Zhang, Y. How significant is a protein structure similarity with TM-score = 0.5? Bioinformatics 26, 889\u2013895 (2010).","DOI":"10.1093\/bioinformatics\/btq066"},{"key":"68761_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pep.2019.04.001","volume":"160","author":"S-M Lee","year":"2019","unstructured":"Lee, S.-M. et al. Expression and purification optimization of an N-terminal Pfs230 transmission-blocking vaccine candidate. Protein Expr. Purif. 160, 56\u201365 (2019).","journal-title":"Protein Expr. Purif."},{"key":"68761_CR52","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1080\/14760584.2019.1578216","volume":"18","author":"HG Kelly","year":"2019","unstructured":"Kelly, H. G., Kent, S. J. & Wheatley, A. K. Immunological basis for enhanced immunity of nanoparticle vaccines. Expert Rev. Vaccines 18, 269\u2013280 (2019).","journal-title":"Expert Rev. Vaccines"},{"key":"68761_CR53","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.vaccine.2013.11.069","volume":"32","author":"L Zhao","year":"2014","unstructured":"Zhao, L. et al. Nanoparticle vaccines. Vaccine 32, 327\u2013337 (2014).","journal-title":"Vaccine"},{"key":"68761_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21251-y","volume":"12","author":"AJ Wargacki","year":"2021","unstructured":"Wargacki, A. J. et al. Complete and cooperative in vitro assembly of computationally designed self-assembling protein nanomaterials. Nat. Commun. 12, 883 (2021).","journal-title":"Nat. Commun."},{"key":"68761_CR55","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature12202","volume":"499","author":"M Kanekiyo","year":"2013","unstructured":"Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102\u2013106 (2013).","journal-title":"Nature"},{"key":"68761_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00653-7","volume":"8","author":"J Ludwig","year":"2023","unstructured":"Ludwig, J. et al. Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in the mouse malaria model. NPJ Vaccines 8, 52 (2023).","journal-title":"NPJ Vaccines"},{"key":"68761_CR57","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJMoa1008115","volume":"365","author":"MA Thera","year":"2011","unstructured":"Thera, M. A. et al. A field trial to assess a blood-stage malaria vaccine. N. Engl. J. Med. 365, 1004\u20131013 (2011).","journal-title":"N. Engl. J. Med."},{"key":"68761_CR58","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1056\/NEJMoa1505819","volume":"373","author":"DE Neafsey","year":"2015","unstructured":"Neafsey, D. E. et al. Genetic diversity and protective efficacy of the RTS,S\/AS01 malaria vaccine. N. Engl. J. Med. 373, 2025\u20132037 (2015).","journal-title":"N. Engl. J. Med."},{"key":"68761_CR59","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1002\/1873-3468.13772","volume":"594","author":"PK Kiyuka","year":"2020","unstructured":"Kiyuka, P. K., Meri, S. & Khattab, A. Complement in malaria: immune evasion strategies and role in protective immunity. FEBS Lett. 594, 2502\u20132517 (2020).","journal-title":"FEBS Lett."},{"key":"68761_CR60","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1128\/JVI.02608-13","volume":"88","author":"D Eggink","year":"2014","unstructured":"Eggink, D., Goff, P. H. & Palese, P. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J. Virol. 88, 699\u2013704 (2014).","journal-title":"J. Virol."},{"key":"68761_CR61","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.1016\/j.vaccine.2014.07.026","volume":"32","author":"T Cardozo","year":"2014","unstructured":"Cardozo, T. et al. Vaccine focusing on cross-subtype HIV-1 gp120 variable loop epitopes. Vaccine 32, 4916\u20134924 (2014).","journal-title":"Vaccine"},{"key":"68761_CR62","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1074\/jbc.M117.816447","volume":"293","author":"H Wang","year":"2018","unstructured":"Wang, H. et al. Epitope-focused immunogens against the CD4-binding site of HIV-1 envelope protein induce neutralizing antibodies against auto- and heterologous viruses. J. Biol. Chem. 293, 830\u2013846 (2018).","journal-title":"J. Biol. Chem."},{"key":"68761_CR63","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1126\/science.1234150","volume":"340","author":"J Jardine","year":"2013","unstructured":"Jardine, J. et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340, 711\u2013716 (2013).","journal-title":"Science"},{"key":"68761_CR64","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01656-18","volume":"93","author":"RP Ringe","year":"2019","unstructured":"Ringe, R. P. et al. Closing and opening holes in the glycan shield of hiv-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes. J. Virol. 93, e01656-18 (2019).","journal-title":"J. Virol."},{"key":"68761_CR65","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/j.jmb.2019.04.016","volume":"431","author":"GE Seabright","year":"2019","unstructured":"Seabright, G. E., Doores, K. J., Burton, D. R. & Crispin, M. Protein and glycan mimicry in HIV vaccine design. J. Mol. Biol. 431, 2223\u20132247 (2019).","journal-title":"J. Mol. Biol."},{"key":"68761_CR66","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2. Cell 183, 1367\u20131382.e17 (2020).","journal-title":"Cell"},{"key":"68761_CR67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abm0899","volume":"14","author":"H-Y Huang","year":"2022","unstructured":"Huang, H.-Y. et al. Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models. Sci. Transl. Med. 14, eabm0899 (2022).","journal-title":"Sci. Transl. Med."},{"key":"68761_CR68","doi-asserted-by":"publisher","first-page":"e0159709","DOI":"10.1371\/journal.pone.0159709","volume":"11","author":"JC Boyington","year":"2016","unstructured":"Boyington, J. C. et al. Structure-based design of head-only fusion glycoprotein immunogens for respiratory syncytial virus. PloS One 11, e0159709 (2016).","journal-title":"PloS One"},{"key":"68761_CR69","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba6466","volume":"5","author":"KA Swanson","year":"2020","unstructured":"Swanson, K. A. et al. A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain. Sci. Immunol. 5, eaba6466 (2020).","journal-title":"Sci. Immunol."},{"key":"68761_CR70","doi-asserted-by":"publisher","DOI":"10.1126\/science.adc9498","volume":"380","author":"EL Shrock","year":"2023","unstructured":"Shrock, E. L. et al. Germline-encoded amino acid-binding motifs drive immunodominant public antibody responses. Science 380, eadc9498 (2023).","journal-title":"Science"},{"key":"68761_CR71","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn8934","volume":"379","author":"A Aung","year":"2023","unstructured":"Aung, A. et al. Low protease activity in B cell follicles promotes retention of intact antigens after immunization. Science 379, eabn8934 (2023).","journal-title":"Science"},{"key":"68761_CR72","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41589-023-01529-6","volume":"20","author":"D Xu","year":"2024","unstructured":"Xu, D. et al. Vaccine design via antigen reorientation. Nat. Chem. Biol. 20, 1012\u20131021 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"68761_CR73","doi-asserted-by":"crossref","unstructured":"Hendricks, G. G. et al. Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice. Sci. Transl. Med. 17, eadu2085 (2025).","DOI":"10.1126\/scitranslmed.adu2085"},{"key":"68761_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00783-y","volume":"9","author":"PV Scaria","year":"2024","unstructured":"Scaria, P. V. et al. mRNA vaccines expressing malaria transmission-blocking antigens Pfs25 and Pfs230D1 induce a functional immune response. NPJ Vaccines 9, 9 (2024).","journal-title":"NPJ Vaccines"},{"key":"68761_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00786-9","volume":"8","author":"N Kunkeaw","year":"2023","unstructured":"Kunkeaw, N. et al. A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax. NPJ Vaccines 8, 187 (2023).","journal-title":"NPJ Vaccines"},{"key":"68761_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00345-0","volume":"6","author":"KL Mallory","year":"2021","unstructured":"Mallory, K. L. et al. Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. NPJ Vaccines 6, 84 (2021).","journal-title":"NPJ Vaccines"},{"key":"68761_CR77","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3390\/pharmaceutics15041223","volume":"15","author":"WL Fotoran","year":"2023","unstructured":"Fotoran, W. L. et al. Establishment of an antiplasmodial vaccine based on PfRH5-encoding rna replicons stabilized by cationic liposomes. Pharmaceutics 15, 1223 (2023).","journal-title":"Pharmaceutics"},{"key":"68761_CR78","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/s41590-023-01562-6","volume":"24","author":"M Ganley","year":"2023","unstructured":"Ganley, M. et al. mRNA vaccine against malaria tailored for liver-resident memory T cells. Nat. Immunol. 24, 1487\u20131498 (2023).","journal-title":"Nat. Immunol."},{"key":"68761_CR79","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1017\/S0031182000062065","volume":"98","author":"T Ponnudurai","year":"1989","unstructured":"Ponnudurai, T. et al. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology 98, 165\u2013173 (1989).","journal-title":"Parasitology"},{"key":"68761_CR80","doi-asserted-by":"publisher","first-page":"899615","DOI":"10.3389\/fimmu.2022.899615","volume":"13","author":"J Ramjith","year":"2022","unstructured":"Ramjith, J. et al. Quantifying reductions in Plasmodium falciparum infectivity to mosquitos: a sample size calculator to inform clinical trials on transmission-reducing interventions. Front. Immunol. 13, 899615 (2022).","journal-title":"Front. Immunol."},{"key":"68761_CR81","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1107\/S0021889807021206","volume":"40","author":"AJ McCoy","year":"2007","unstructured":"McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658\u2013674 (2007).","journal-title":"J. Appl. Crystallogr."},{"key":"68761_CR82","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1107\/S0907444909052925","volume":"66","author":"PD Adams","year":"2010","unstructured":"Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D. Biol. Crystallogr. 66, 213\u2013221 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"68761_CR83","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1107\/S0907444910007493","volume":"66","author":"P Emsley","year":"2010","unstructured":"Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 66, 486\u2013501 (2010).","journal-title":"Acta Crystallogr. D. Biol. Crystallogr."},{"key":"68761_CR84","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01456","volume":"2","author":"A Morin","year":"2013","unstructured":"Morin, A. et al. Collaboration gets the most out of software. eLife 2, e01456 (2013).","journal-title":"eLife"},{"key":"68761_CR85","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"68761_CR86","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","volume":"19","author":"M Mirdita","year":"2022","unstructured":"Mirdita, M. et al. ColabFold: making protein folding accessible to all. Nat. Methods 19, 679\u2013682 (2022).","journal-title":"Nat. Methods"},{"key":"68761_CR87","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jsb.2013.11.002","volume":"185","author":"CR Marr","year":"2014","unstructured":"Marr, C. R., Benlekbir, S. & Rubinstein, J. L. Fabrication of carbon films with \u223c500\u2009nm holes for cryo-EM with a direct detector device. J. Struct. Biol. 185, 42\u201347 (2014).","journal-title":"J. Struct. Biol."},{"key":"68761_CR88","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1107\/S205225252000929X","volume":"7","author":"H Guo","year":"2020","unstructured":"Guo, H. et al. Electron-event representation data enable efficient cryoEM file storage with full preservation of spatial and temporal resolution. IUCrJ 7, 860\u2013869 (2020).","journal-title":"IUCrJ"},{"key":"68761_CR89","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"68761_CR90","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s41592-019-0575-8","volume":"16","author":"T Bepler","year":"2019","unstructured":"Bepler, T. et al. Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs. Nat. Methods 16, 1153\u20131160 (2019).","journal-title":"Nat. Methods"},{"key":"68761_CR91","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/pro.3235","volume":"27","author":"TD Goddard","year":"2018","unstructured":"Goddard, T. D. et al. UCSF ChimeraX: meeting modern challenges in visualization and analysis. Protein Sci. Publ. Protein Soc. 27, 14\u201325 (2018).","journal-title":"Protein Sci. Publ. Protein Soc."},{"key":"68761_CR92","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1107\/S1600576720013412","volume":"54","author":"K Manalastas-Cantos","year":"2021","unstructured":"Manalastas-Cantos, K. et al. ATSAS 3.0: expanded functionality and new tools for small-angle scattering data analysis. J. Appl. Crystallogr. 54, 343\u2013355 (2021).","journal-title":"J. Appl. Crystallogr."},{"key":"68761_CR93","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1107\/S0021889892001663","volume":"25","author":"DI Svergun","year":"1992","unstructured":"Svergun, D. I. Determination of the regularization parameter in indirect-transform methods using perceptual criteria. J. Appl. Crystallogr. 25, 495\u2013503 (1992).","journal-title":"J. Appl. Crystallogr."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68761-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68761-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68761-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:07:28Z","timestamp":1772024848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-68761-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":93,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["68761"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-68761-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"22 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. Patent applications have been filed that relate to this work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2010"}}